Literature DB >> 19021638

CHD7 mutations in patients initially diagnosed with Kallmann syndrome--the clinical overlap with CHARGE syndrome.

M C J Jongmans1, C M A van Ravenswaaij-Arts, N Pitteloud, T Ogata, N Sato, H L Claahsen-van der Grinten, K van der Donk, S Seminara, J E H Bergman, H G Brunner, W F Crowley, L H Hoefsloot.   

Abstract

Kallmann syndrome (KS) is the combination of hypogonadotropic hypogonadism and anosmia or hyposmia, two features that are also frequently present in CHARGE syndrome. CHARGE syndrome is caused by mutations in the CHD7 gene. We performed analysis of CHD7 in 36 patients with KS and 20 patients with normosmic idiopathic hypogonadotropic hypogonadism (nIHH) in whom mutations in KAL1, FGFR1, PROK2 and PROKR2 genes were excluded. Three of 56 KS/nIHH patients had de novo mutations in CHD7. In retrospect, these three CHD7-positive patients showed additional features that are seen in CHARGE syndrome. CHD7 mutations can be present in KS patients who have additional features that are part of the CHARGE syndrome phenotype. We did not find mutations in patients with isolated KS. These findings imply that patients diagnosed with hypogonadotropic hypogonadism and anosmia should be screened for clinical features consistent with CHARGE syndrome. If such features are present, particularly deafness, dysmorphic ears and/or hypoplasia or aplasia of the semicircular canals, CHD7 sequencing is recommended.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19021638      PMCID: PMC2854009          DOI: 10.1111/j.1399-0004.2008.01107.x

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  20 in total

1.  Mutations in a new member of the chromodomain gene family cause CHARGE syndrome.

Authors:  Lisenka E L M Vissers; Conny M A van Ravenswaaij; Ronald Admiraal; Jane A Hurst; Bert B A de Vries; Irene M Janssen; Walter A van der Vliet; Erik H L P G Huys; Pieter J de Jong; Ben C J Hamel; Eric F P M Schoenmakers; Han G Brunner; Joris A Veltman; Ad Geurts van Kessel
Journal:  Nat Genet       Date:  2004-08-08       Impact factor: 38.330

2.  A gene deleted in Kallmann's syndrome shares homology with neural cell adhesion and axonal path-finding molecules.

Authors:  B Franco; S Guioli; A Pragliola; B Incerti; B Bardoni; R Tonlorenzi; R Carrozzo; E Maestrini; M Pieretti; P Taillon-Miller; C J Brown; H F Willard; C Lawrence; M Graziella Persico; G Camerino; A Ballabio
Journal:  Nature       Date:  1991-10-10       Impact factor: 49.962

3.  Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome.

Authors:  Catherine Dodé; Jacqueline Levilliers; Jean-Michel Dupont; Anne De Paepe; Nathalie Le Dû; Nadia Soussi-Yanicostas; Roney S Coimbra; Sedigheh Delmaghani; Sylvie Compain-Nouaille; Françoise Baverel; Christophe Pêcheux; Dominique Le Tessier; Corinne Cruaud; Marc Delpech; Frank Speleman; Stefan Vermeulen; Andrea Amalfitano; Yvan Bachelot; Philippe Bouchard; Sylvie Cabrol; Jean-Claude Carel; Henriette Delemarre-van de Waal; Barbara Goulet-Salmon; Marie-Laure Kottler; Odile Richard; Franco Sanchez-Franco; Robert Saura; Jacques Young; Christine Petit; Jean-Pierre Hardelin
Journal:  Nat Genet       Date:  2003-03-10       Impact factor: 38.330

4.  Olfactory evaluation in children: application to the CHARGE syndrome.

Authors:  Christel Chalouhi; Patrick Faulcon; Christine Le Bihan; Lucie Hertz-Pannier; Pierre Bonfils; Véronique Abadie
Journal:  Pediatrics       Date:  2005-06-15       Impact factor: 7.124

5.  Spectrum of CHD7 mutations in 110 individuals with CHARGE syndrome and genotype-phenotype correlation.

Authors:  Seema R Lalani; Arsalan M Safiullah; Susan D Fernbach; Karine G Harutyunyan; Christina Thaller; Leif E Peterson; John D McPherson; Richard A Gibbs; Lisa D White; Margaret Hefner; Sandra L H Davenport; John M Graham; Carlos A Bacino; Nancy L Glass; Jeffrey A Towbin; William J Craigen; Steven R Neish; Angela E Lin; John W Belmont
Journal:  Am J Hum Genet       Date:  2005-12-29       Impact factor: 11.025

6.  Vestibular anomalies in CHARGE syndrome: investigations on and consequences for postural development.

Authors:  V Abadie; S Wiener-Vacher; M P Morisseau-Durand; C Porée; J Amiel; L Amanou; C Peigné; S Lyonnet; Y Manac'h
Journal:  Eur J Pediatr       Date:  2000-08       Impact factor: 3.183

7.  CHARGE syndrome includes hypogonadotropic hypogonadism and abnormal olfactory bulb development.

Authors:  G Pinto; V Abadie; R Mesnage; J Blustajn; S Cabrol; J Amiel; L Hertz-Pannier; A M Bertrand; S Lyonnet; R Rappaport; I Netchine
Journal:  J Clin Endocrinol Metab       Date:  2005-07-19       Impact factor: 5.958

8.  Clinical assessment and mutation analysis of Kallmann syndrome 1 (KAL1) and fibroblast growth factor receptor 1 (FGFR1, or KAL2) in five families and 18 sporadic patients.

Authors:  Naoko Sato; Noriyuki Katsumata; Masayo Kagami; Tomonobu Hasegawa; Naoaki Hori; Setsuyo Kawakita; Shigeru Minowada; Aki Shimotsuka; Yoshimasa Shishiba; Masato Yokozawa; Toshiyuki Yasuda; Keisuke Nagasaki; Daiichiro Hasegawa; Yukihiro Hasegawa; Katsuhiko Tachibana; Yasuhiro Naiki; Reiko Horikawa; Toshiaki Tanaka; Tsutomu Ogata
Journal:  J Clin Endocrinol Metab       Date:  2004-03       Impact factor: 5.958

9.  Exon copy number alterations of the CHD7 gene are not a major cause of CHARGE and CHARGE-like syndrome.

Authors:  Jorieke E H Bergman; Ilse de Wijs; Marjolijn C J Jongmans; Ronald J Admiraal; Lies H Hoefsloot; Conny M A van Ravenswaaij-Arts
Journal:  Eur J Med Genet       Date:  2008-04-04       Impact factor: 2.708

10.  The candidate gene for the X-linked Kallmann syndrome encodes a protein related to adhesion molecules.

Authors:  R Legouis; J P Hardelin; J Levilliers; J M Claverie; S Compain; V Wunderle; P Millasseau; D Le Paslier; D Cohen; D Caterina
Journal:  Cell       Date:  1991-10-18       Impact factor: 41.582

View more
  73 in total

1.  Commentary: the year in endocrine genetics for basic scientists.

Authors:  William F Crowley
Journal:  Mol Endocrinol       Date:  2011-11-22

Review 2.  Neural crest and olfactory system: new prospective.

Authors:  Paolo E Forni; Susan Wray
Journal:  Mol Neurobiol       Date:  2012-07-08       Impact factor: 5.590

Review 3.  Chromodomain proteins in development: lessons from CHARGE syndrome.

Authors:  W S Layman; E A Hurd; D M Martin
Journal:  Clin Genet       Date:  2010-04-08       Impact factor: 4.438

4.  Atypical phenotypes associated with pathogenic CHD7 variants and a proposal for broadening CHARGE syndrome clinical diagnostic criteria.

Authors:  Caitlin L Hale; Adrienne N Niederriter; Glenn E Green; Donna M Martin
Journal:  Am J Med Genet A       Date:  2015-11-21       Impact factor: 2.802

Review 5.  Neonatal gonadotropin therapy in male congenital hypogonadotropic hypogonadism.

Authors:  Claire Bouvattier; Luigi Maione; Jérôme Bouligand; Catherine Dodé; Anne Guiochon-Mantel; Jacques Young
Journal:  Nat Rev Endocrinol       Date:  2011-10-18       Impact factor: 43.330

6.  Prevalence of genetic testing in CHARGE syndrome.

Authors:  Timothy S Hartshorne; Kasee K Stratton; Conny M A van Ravenswaaij-Arts
Journal:  J Genet Couns       Date:  2010-09-28       Impact factor: 2.537

7.  Clinical utility gene card for: CHARGE syndrome.

Authors:  Kim Blake; Conny M A van Ravenswaaij-Arts; Lies Hoefsloot; Alain Verloes
Journal:  Eur J Hum Genet       Date:  2011-03-16       Impact factor: 4.246

8.  Autism-linked CHD gene expression patterns during development predict multi-organ disease phenotypes.

Authors:  Sahrunizam Kasah; Christopher Oddy; M Albert Basson
Journal:  J Anat       Date:  2018-10-02       Impact factor: 2.610

9.  Prioritizing genetic testing in patients with Kallmann syndrome using clinical phenotypes.

Authors:  Flavia Amanda Costa-Barbosa; Ravikumar Balasubramanian; Kimberly W Keefe; Natalie D Shaw; Nada Al-Tassan; Lacey Plummer; Andrew A Dwyer; Cassandra L Buck; Jin-Ho Choi; Stephanie B Seminara; Richard Quinton; Dorota Monies; Brian Meyer; Janet E Hall; Nelly Pitteloud; William F Crowley
Journal:  J Clin Endocrinol Metab       Date:  2013-03-26       Impact factor: 5.958

10.  CHD7 targets active gene enhancer elements to modulate ES cell-specific gene expression.

Authors:  Michael P Schnetz; Lusy Handoko; Batool Akhtar-Zaidi; Cynthia F Bartels; C Filipe Pereira; Amanda G Fisher; David J Adams; Paul Flicek; Gregory E Crawford; Thomas Laframboise; Paul Tesar; Chia-Lin Wei; Peter C Scacheri
Journal:  PLoS Genet       Date:  2010-07-15       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.